English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Levetiracetam (LEV) is a novel anti-epileptic agent. The chemical name of LEV, a single enantiomer is (-)-(S)-α-ethyl2-oxo-1-pyrrolidine acetamide. [1] The chemical structure of LEV is shown in Figure 1. Its molecular formula is C8H14N2O2 and its molecular weight is 170.21. It is chemically unrelated with existing anti-epileptic drugs, differing in structure and pharmacology [2, 3]. This is a structural analogue of piracetam, which binds to a synaptic vesicle protein SV2A and is believed to impede nerve conduction across synapses. The exact mechanism by which Levetiracetam shows its antiepileptic effect is still unknown. However, it is believed that it binds to a synaptic vesicle protein, thus slowing down nerve conduction across synapses [4]. Levetiracetam is approved by the U.S. Food and Drug Administration as an adjunct in partial on set seizures, myoclonic seizures and primary generalized tonic-clonic seizures and mono therapy for partial seizures with or without secondary generalization. Levetiracetam has possible benefits for other psychiatric and neurologic conditions4 such as Tourette syndrome, autism, and anxiety disorders [4, 5].

Simultaneous Estimation of Levetiracetam and its Preservatives In Oral Liquid Dosage form by Rp-Hplc Method